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Abstract
Heart failure with preserved ejection fraction (HFpEF) is a disease with limited evidence-based treatment options.Mineralocorticoid
receptor antagonists (MRA) offer benefit in heart failure with reduced ejection fraction (HFrEF), but their impact in HFpEF remains
unclear. We therefore evaluated the effect of MRA on echocardiographic, functional, and systemic parameters in patients with
HFpEF by a systematic review and meta-analysis. We searched MEDLINE, EMBASE, clinicaltrials.gov, and Cochrane Clinical
Trial Collection to identify randomized controlled trials that (a) compared MRAversus placebo/control in patients with HFpEF and
(b) reported echocardiographic, functional, and/or systemic parameters relevant to HFpEF. Studies were excluded if: they enrolled
asymptomatic patients; patients with HFrEF; patients after an acute coronary event; compared MRA to another active comparator;
or reported a follow-up of less than 6 months. Primary outcomes were changes in echocardiographic parameters. Secondary end-
points were changes in functional capacity, quality of life measures, and systemic parameters. Quantitative analysis was performed
by generating forest plots and calculating effect sizes by random-effect models. Between-study heterogeneity was assessed through
Q and I2 statistics. Nine trials with 1164 patients were included. MRA significantly decreased E/e′ (mean difference − 1.37, 95%
confidence interval − 1.72 to − 1.02), E/A (− 0.04, − 0.08 to 0.00), left ventricular end-diastolic diameter (− 0.78 mm, − 1.34 to − 0.
22), left atrial volume index (− 1.12 ml/m2, − 1.91 to − 0.33), 6-min walk test distance (− 11.56 m, − 21 to − 2.13), systolic (− 4.75
mmHg, − 8.94 to − 0.56) and diastolic blood pressure (− 2.91 mmHg, − 4.15 to − 1.67), and increased levels of serum potassium (0.
23 mmol/L, 0.19 to 0.28) when compared with placebo/control. In patients with HFpEF, MRA treatment significantly improves
indices of cardiac structure and function, suggesting a decrease in left ventricular filling pressure and reverse cardiac remodeling.
MRA increase serum potassium and decrease blood pressure; however, a small decrease in 6-min-walk distance is also noted. Larger
prospective studies are warranted to provide definitive answers on the effect of MRA in patients with HFpEF.
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Introduction
Heart failure (HF) with preserved ejection fraction (HFpEF) is
a clinical entity for which few evidence-based treatments exist
[1]. Mineralocorticoid receptor antagonists (MRA), which
represent a cornerstone treatment for patients with HF with
reduced ejection fraction (HFrEF), failed to decrease mortality
in HFpEF patients in a large, multi-center trial [2].
Nevertheless, the significant criticism pertaining to the trial’s
design and execution [3, 4], combined with the paucity of
other relevant, large data have resulted in uncertainty regard-
ing the use of MRA in HFpEF. A small number of well-
performed randomized studies have reported positive results
with the use of MRA in HFpEF when assessing cardiac func-
tion by echocardiographic or patients’ functional status [5–9].
Still, the most recent European Society of Cardiology
Guidelines state that Bevidence that MRA improve symptoms
in these patients is lacking^, while no reference is made to the
reported effects of MRA on cardiac function and structure, as
well as other systemic parameters [1]. On the other hand, US
guidelines take a more definitive, though guarded stance (IIB
recommendation) [10], in view of the positive impact ofMRA
observed on ventricular remodeling [11], favorable adapta-
tions in echocardiographic parameters of diastolic function,
and subgroup analysis of a secondary hospitalization endpoint
from a clinical trial [12, 13]. Given that a significant body of
literature has been published since the last relevant meta-
analysis of randomized trials [14–18], a new meta-analysis
on the topic seems timely and warranted. Inclusion of data
on functional and systemic parameters, apart from echocardio-
graphic indices, would further strengthen the rationale for
performing the meta-analysis.
The objective of the current study was to critically assess
the effect of MRA on echocardiographic, functional, and sys-
temic parameters in adult patients with HFpEF included in
randomized controlled trials.
Methods
The present study was conducted according to the PRISMA
statement (Table A1-Appendix) [19]. The review protocol has
been registered in PROSPERO: International Prospective
R e g i s t e r o f S y s t e m a t i c R e v i e w s ( N um b e r :
CRD42018104929) www.crd.york.ac.uk/PROSPERO/
display_record.php?ID=CRD42018104929, Accessed 18
August 2018.
Identification and selection of studies
MEDLINE, EMBASE, clinicaltrials.gov, and Cochrane
Clinical Trial Collection were searched on June 15, 2018
with a combinatorial approach (Boolean operator BAND^)
of three broader search terms. The broader search terms
were derived using the Boolean operator BOR^ between
synonyms for Bheart failure,^ Bpreserved ejection fraction,^
and Bmineralocorticoid receptor antagonists.^ Detailed
descriptions of the terms used for MEDLINE and EMBASE
searches are outlined in the Appendix Tables A2 and A3. The
search was restricted to the period from January 1, 2000
onwards, out of concern for a high risk of imprecision in the
clinical diagnosis of HFpEF prior to 2000. Only articles
written in English were eligible, while there was no
restriction regarding publication status. The reference lists
from previous systematic reviews relevant to our topic were
hand-screened for studies [11, 14, 20], whereas references of
the included articles were screened for additional studies. If
needed, authors were contacted to request unpublished origi-
nal papers or further details not available on the official
version.
Study eligibility criteria included: (a) comparison of MRA
(spironolactone, eplerenone, canrenone) with placebo/control;
(b) adult patients diagnosed with HFpEF; (c) follow-up ≥
6 months, as administration of MRA for a shorter period
was considered unlikely to produce significant functional
and echocardiographic changes; and (d) report of the out-
comes of interest (Table 1). HFpEF definition included pa-
tients with HF symptoms and left ventricular ejection fraction
(LVEF) ≥ 45%. There was no cut-off for natriuretic peptides
or cardiac abnormalities as these criteria have been recently
established by guidelines and would have excluded most of
the older trials. We excluded studies if they included patients
with previous history of myocardial infarction or compared
MRA with another active comparator. Ethical approval was
not required, as no patients were recruited.
The search was independently performed by two reviewers
(MML and TN). End-note was used to remove duplicates. All
titles and abstracts were screened individually by all four re-
viewers, in order to select those that met the inclusion criteria.
Differences in assessment of eligibility between reviewers
were resolved through discussion and consensus.
Risk of bias
Risk of bias (RoB) within studies was assessed using the
Cochrane Risk of Bias Tool. The assessment was performed
at the study level and regarded components recommended by
the Cochrane Collaboration for randomized trials, namely ran-
domization sequence generation, treatment allocation con-
cealment, blinding, completeness of outcome data, and selec-
tive outcome [21]. For each component, trials were catego-
rized as low, high, or unclear risk of bias. Studies that were
deemed to be at high risk of bias would only be included in the
systematic review but not in the meta-analysis.
Risk of bias across studies was evaluated by assessing pub-
lication bias and selective reporting within studies. In order to
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explore publication bias (meta-bias), unpublished information
was meticulously searched so that it could be incorporated to
quantitative analysis. Α list of the conference databases that
were searched to this end is given in Table A4 (Appendix). We
assessed quality of evidence for outcomes using GRADE
criteria [22].
In addition, protocol registries (clinicaltrials.gov and
PROSPERO) were scanned to assess selective outcome
reporting. All four reviewers performed their personal
assessment and any disagreements were discussed until
consensus was reached.
Data extraction
A systematic approach was used to extract the relevant vari-
ables from the selected studies. The variables for which data
were sought are shown in detail in Table A5 (Appendix) and
regarded study identity and design, patient population, inter-
vention, and outcomes. Outcome parameters were divided
into three groups: echocardiographic, functional, and systemic
parameters. Echocardiographic parameters were prioritized
over the other parameters as primary outcomes, as they are
systematically measured and reported in relevant studies.
Furthermore, several echocardiographic indices (LAVi, E/e′)
have been recognized as significant predictors of prognosis in
patients with HFpEF [23, 24], thus entailing clinical implica-
tions to our analysis. Volumetric echocardiographic parame-
ters that were not indexed were not included. Quality of life
(QoL) changes should have been estimated with either Kansas
City Questionnaire (KCCQ) or the Minneapolis Living With
Heart Failure Questionnaire (MLWHFQ). All four reviewers
extracted study characteristics and data input was cross-
validated between reviewer databases.
Qualitative and statistical analysis
Data were combined in a systematic review, forest plots and, if
appropriate, in a meta-analysis. We set three studies as the
minimum number for quantitative synthesis of data in a
meta-analysis for each study parameter. Given that all out-
comes were continuous variables, mean differences were used
as effect measures. For those parameters, which were indexed
to diverging bases across studies (i.e., left ventricular mass
index, LVMI) or quantified by different measurement
techniques (i.e., BNP and NT-proBNP), standardized mean
differences by the method of Hedges were used. When not
available, standard deviations were derived from confidence
intervals according to the Cochrane Handbook for Systematic
Reviews of Interventions or from median with interquartile
ranges according to Wan et al. [21, 25]. Missing standard
deviations for the difference between treatment and control
group were also calculated according to the Cochrane
Handbook for Systematic Reviews of Interventions [21].
Our data was expected to be heterogeneous due to the rel-
atively small sample sizes and the diversity in study design.
Consequently, analysis was performed with random effect
models. Heterogeneity was assessed by the Q statistic; how-
ever, due to its limited power to rule out heterogeneity, a p
value threshold of 0.10 was used. A quantitative analysis of
the impact of heterogeneity using the I2 statistic was also per-
formed. I2 values > 50% were considered as highly heteroge-
nous. In order to evaluate the effect of imputing standard de-
viations of within-group changes, a sensitivity analysis for
different values of correlation coefficients (0.7, 0.9, and 0.8
or calculated based on given study data) was performed.
Although performance of three subgroup analyses to ex-
plore heterogeneity had been pre-specified (multi-center vs
single-center studies, studies with high percentage of women
vs even gender distribution and studies with high vs low base-
line use of diuretics), subgroup analysis was not considered
feasible due to the small number of studies. For the same
reason, we also decided not to perform meta-regression anal-
yses and funnel plots with the trial mean differences to explore
meta-bias. All p values were two-tailed with statistical signif-
icance set at 0.05 (if not otherwise specified) and confidence
intervals (CI) computed at 95% level. All analyses were per-
formed with the use of Stata 15 Software (StataCorp LLC,
Texas, US).
Results
Identified and eligible studies
The number of identified and screened studies is indicated in
Fig. 1.
Our initial search identified 1253 studies from 2000 on-
wards; after removal of duplicates, screening of titles,
Table 1 Primary and secondary
outcomes included in the analysis Primary Echocardiographic parameters (E/e′, E/A, deceleration time, LVEDD, LVEF, LAVi, LVMi)
Secondary A. Functional parameters (VO2 peak, 6MWD, NYHA, QoL)
B. Systemic parameters (SBP, DBP, natriuretic peptides, serum potassium)
DBP diastolic blood pressure, LAVi left atrial volume index, LVMi left ventricular mass index, LVEDD left
ventricular end-diastolic diameter, LVEF left ventricular ejection fraction, NYHA New York Heart Association,
QoL quality of life, SBP systolic blood pressure, VO2 oxygen consumption, 6MWD 6-min walk test distance
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abstracts, and full-texts and adding studies from previous anal-
yses up to 2014, 12 studies were included in the qualitative
synthesis (Table 2). Of these, three studies were not suitable
for data extraction, which resulted in nine studies amenable
for inclusion in the meta-analysis.
Characteristics of included studies
The studies enrolled 1164 patients (588 patients in the
MRA and 576 in the control/placebo arm) who were
followed for up to 18 months. Of the included trials, sev-
en included patients with a left ventricular ejection frac-
tion ≥ 50% and eight were placebo controlled. In seven
studies, the administered MRA was spironolactone, while
in the remaining two studies eplerenone. The baseline
characteristics and the reported clinical, echocardiograph-
ic parameters and systemic parameters are indicated for
each study in Table A6 (Appendix).
Risk of bias within studies
During quality assessment, issues regarding random sequence
generation were observed in 5 studies. Protocol deviations,
incomplete outcome data and selective reporting of results
were not observed in any of the selected studies. Details of
RoB assessment are given in Fig. 2.
Risk of bias across studies
Multiple conference databases as well as protocol registries
were scanned for other studies that could be relevant to our
meta-analysis. Our search did not produce any results that
could indicate any concerns regarding publication or selective
outcome reporting biases.
Results of individual studies and synthesis of results
Echocardiographic parameters
Echocardiographic parameters were frequently measured
and reported among studies. Eight studies reported E/A
and E/e′, while seven studies provided data on decelera-
tion time (DT). Six studies included data on left ventric-
ular mass index (LVMi) and ejection fraction (LVEF) and
four on left ventricular end-diastolic diameter (LVEDD).
Finally, values for left atrial volume index (LAVi) were
provided by five studies.
MRA compared to placebo/control significantly
decreased E/e′ (mean difference [MD]: − 1.37;
95% CI: − 1.02 to − 1.72; comparison p < 0.001;
heterogeneity p = 0.437; I2 = 0.0%), E/A (MD: −
0.04; 95% CI: − 0.08 to 0.0; comparison p =
0.046; heterogeneity p = 0.491; I2 = 0.0%), LVEDD
(MD: − 0.78 mm; 95% CI: − 1.34 to − 0.22;
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Fig. 1 PRISMA flow chart of
study identification and selection
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comparison p = 0.006; heterogeneity p = 0.632; I2 = 0.0%),
and LAVi (MD: − 1.12 ml/m2; 95% CI: − 1.91 to − 0.33;
comparison p = 0.005; heterogeneity p = 0.389; I2 = 3.1%)
(Fig. 3).
Table 2 Characteristics of studies included in the qualitative analysis
Systemic 
Parameters
SBP, DBP
BNP, 
serum potassium, 
SBP, DPB
BNP,
SBP, DPB 
NT-pro-BNP, 
serum potassium,
SBP, DPB
BNP
Baseline echocardiography reported, but no 
longitudinal follow-up
Echocardiographic study but no detailed results 
available, abstract of congress presentation.
not reported
KCCQ, EQ5D-VAS but only reported graphically, 
without size of treatment groups
BNP,
serum potassium,
SBP, DPB
BNP;
SBP, DPB
SBP, DPB
a
Studies in white are from previous meta-analyses. Studies in color are de novo identified studies, those in red not suitable for 
meta-analysis.
b
HFpEF: heart Failure with preserved ejection fraction, mo: months, BNP: brain natriuretic peptide, SBP: systolic blood pressure, 
DBP: diastolic blood pressure
Echocardiographic
Parameters
E/A, E decel time,
LVEDD
E/A,  E/e,  E decel 
time, LVEF, LVMI, 
LAVI
E/A,  E/e,  E decel 
time, LVEDD, 
LVMI 
E/A,  E/e,  E decel 
time, LVEDD, 
LVEF, LVMI, 
E/A,  E/e,  E decel 
time, LVMI, LAVI
E/A,  E/e, LVEF, 
LVMI
E/A,  E/e,  E decel 
time, LVEDD, 
LVEF, LVMI, LAVI
E/A,  E/e,  E decel 
time, LVEF
E/e‘,  E decel time  
LVEF, LAVI
Clinical 
Parameters
not reported
MLHFQ score
6mwd, 
NYHA class,
KCCQ score
peak VO2, 
6mwd, 
NYHA class,
6mwd, 
NYHA class, 
KCCQ score
not reported
peak VO2, 
exercise 
capacity (Bruce)
peak VO2, 
6mwd, 
MLHFQ score
peak VO2, 
exercise 
capacity (Bruce)
Control
group
placebo
untreated
placebo
placebo
placebo
placebo
standard 
therapy
placebo
placebo
placebo
placebo
placebo
MRA Dosing
(spironolactone 
if not indicated 
otherwise)
25 mg
eplerenone up to 
50 mg
eplerenone up to 
50 mg
25 mg
25 mg
15 to 45 mg
25 to 50 mg
15 to 45 mg
15 to 45 mg
25 mg
25 mg
25 mg
Control
(n)
15
20
23
209
24
total 935
total 79
118
n.r.
75
38
54
MRA 
(n)
15
24
23
213
24
121
n.r.
75
42
51
Length 
of 
Follow-
up
6 mo
12 mo
6 mo
12 mo
6 mo
median 
35 mo
6 mo
12-18 
mo
up to 
36 mo
6 mo
9 mo
6 mo
Study (year)
Mottram 
(Circulation, 
2004)(23)
Mak 
(JACC, 2009)(24)
RAAM-PEF, 
Deswal 
(JCF, 2011)(25)
Aldo-DHF, 
Edelmann 
(JAMA, 2013)(26)
Kurrelmeyer 
(JCF, 2014)(27)
TOPCAT-Echo, 
Shah 
(Circ Heart Fail, 
2014)(6)
Karapysh 
(Eur J Heart Fail 
suppl, 2015)(7)
TOPCAT-
serialEcho, Shah 
(Circ Heart Fail, 
2015)(8)
TOPCAT-QoL, 
Lewis  
(Circ Heart Fail, 
2016)(10)
STRUCTURE, 
Kosmala (JACC, 
2016)(9)
Upadhya 
(JAGS, 2017)(12)
Kosmala 
(J Am Coll 
Cardiol Img, 
2017)(11)
Studies in white are from previous meta-analyses. Studies in color are de novo identified studies, those in red not suitable for meta-analysis
HFpEF heart failure with preserved ejection fraction, mo months, BNP brain natriuretic peptide, SBP systolic blood pressure, DBP diastolic blood
pressure
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On the contrary, MRA compared to placebo/control did not
significantly affect DT (MD: − 8.38 ms; 95% CI: − 21.76 to
5.00; comparison p = 0.220; heterogeneity p < 0.001; I 2 =
85.5%), LVEF (MD: 0.62%; 95% CI: − 0.65 to 1.88; compar-
ison p = 0.340; heterogeneity p = 0.155; I2 = 37.7%), and
LVMi (standardized MD: − 0.12; 95% CI: − 0.50 to 0.27;
comparison p = 0.550; heterogeneity p < 0.001; I2 = 84.5%)
(Appendix Fig. 1).
Functional parameters
Functional parameters were assessed and reported in less than
50% of included studies. Four studies reported maximum rate
of oxygen consumption (VO2 peak), 6-min walk test distance
(6-MWD), and New York Heart Association (NYHA) class.
Quality of life (QoL) metrics were assessed and presented in
five studies.
a b
c d
Study ID
Mak (2009)
Deswal (2011)
Edelmann (2013)
Kurrelmeyer (2014)
Shah (2015)
Kosmala (2016)
Kosmala (2017)
Upadhya (2017)
Overall (I-squared= 0.0%, p=0.437)
Test for overall eﬀect: Z=7.66 (p<0.001) 
Mean 
diﬀerence in 
E/e’ (95% CI)
%
weight
-1.70 (-3.35, -0.05) 4.47
-3.00 (-5.02, -0.98)
-1.40 (-1.91, -0.89)
-2.00 (-3.51, -0.49)
-0.20 (-1.44,  1.04)
-1.40 (-2.28, -0.52)
-1.10 (-2.36,  0.16)
-1.30 (-2.44, -0.16)
-1.37 (-1.72, -1.02)
2.99
46.45
5.32
7.89
15.76
7.68
9.44
100.00
Study ID
Moram (2004)
Mak (2009)
Deswal (2011)
Edelmann (2013)
Kurrelmeyer (2014)
Shah (2015)
Kosmala (2016)
Upadhya (2017)
Overall (I-squared= 0.0%, p=0.491)
Test for overall eﬀect: Z=2.00 (p=0.046) 
Mean 
diﬀerence in 
E/A (95% CI)
%
weight
-0.03 (-0.15, 0.09) 11.07
0.03 (-0.20, 0.30) 2.78
-0.07 (-0.44, 0.30) 1.10
-0.03 (-0.09, 0.03) 46.13
-0.20 (-0.55, 0.15) 1.23
-0.14 (-0.24, -0.04) 13.91
7.830.05 (-0.09, 0.19)
-0.03 (-0.13, 0.07) 15.95
-0.04 (-0.08, -0.00) 100.00
Favors MRA                                      Favors Control          Favors MRA                                      Favors Control          
Study ID
Mean 
diﬀerence in 
LVEDD (95% CI)
%
weight
Moram (2004)
Deswal (2011)
Edelmann (2013)
Kosmala (2016)
Overall (I-squared= 0.0%, p=0.632)
Test for overall eﬀect: Z=2.72 (p=0.006) 
-0.50 (-3.01,  2.01) 5.01
-1.00 (-3.01,  1.01) 7.81
52.17-1.10 (-1.88, -0.32)
-0.30 (-1.25,  0.65) 35.00
100.00-0.78 (-1.34, -0.22)
Study ID
Mean 
diﬀerence in 
LAVi (95% CI)
%
weight
Mak (2009)
Edelmann (2013)
Kurrelmeyer (2014)
Kosmala (2016)
Kosmala (2017)
Overall (I-squared= 3.1%, p=0.389)
Test for overall eﬀect: Z=2.79 (p=0.005) 
-2.30 (-10.41, 5.81) 0.94
-0.50 (-1.56, 0.56) 50.48
-0.20 (-2.98, 2.58) 7.89
-1.90 (-3.58, -0.22) 21.09
-2.20 (-3.94, -0.46) 19.61
-1.12 (-1.91, -0.33) 100.00
Favors MRA                                      Favors Control          Favors MRA                                      Favors Control          
Fig. 3 Mean difference estimates of A E/e′, B E/A, C left ventricular end-diastolic diameter (LVEDD), and D left atrial volume index (LAVi) of MRA
versus control
Randomizaon
process
Deviaons from 
intended 
intervenons
Missing outcome 
data
Measurement of 
the outcome
Selecon of the 
reported result
Overall bias
Moram 2004
Mak 2009
Deswal 2011
Edelman 2013
Kurrelmeyer 2014
Shah 2015
Kosmala 2016
Upadhya 2017
Kosmala 2017
Low risk of bias Unclear risk of bias High risk of bias
Fig. 2 Risk of bias assessment for
studies included in the meta-
analysis
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MRA compared to placebo/control, did not significantly
increase VO2 peak (MD: 1.22 ml/kg/min; 95% CI: − 0.33 to
2.77; comparison p = 0.124; heterogeneity p < 0.001; I2 =
90.8%), while they significantly decreased 6-MWD (MD: −
11.56 m; 95% CI: − 21 to − 2.1; comparison p = 0.016; het-
erogeneity p = 0.522; I2 = 0.0%) (Fig. 4).
Among other measures of functional status, NYHA
class was treated as a categorical rather than a continu-
ous variable in three out of four studies, rendering the
pooling of effect estimates unfeasible. Regarding QoL
measures, two studies used the KCCQ, in this way not
fulfilling the pre-specified cut-off for quantitative syn-
thesis. Three studies used the MLWHFQ; MRA use
did not significantly affect MLWHFQ (MD: − 1.15;
95% CI: − 3.00 to 0.693; comparison p = 0.221; hetero-
geneity p = 0.597; I2 = 0.0%) (Appendix Fig. 2).
Furthermore, as the two questionnaires have inverse di-
rections for high-quality (MLWHFQ scale of 0–105
with higher scores indicating lower QoL and KCCQ
scale of 0–100 with higher scores indicating higher
QoL) pooling of estimates with standardized effect sizes
was considered inappropriate.
Systemic parameters
Systolic and diastolic blood pressure were common outcomes
among the included studies, as they were reported in seven of
them. On the other hand, serum potassium and blood levels of
natriuretic peptides (BNP/NT-proBNP) were uncommon out-
comes, as they were measured in three and four studies,
respectively.
Among HFpEF patients, MRA treatment compared to
placebo/control significantly decreased systolic (MD: −
4.75 mmHg; 95% CI: − 8.94 to − 0.56; comparison p =
0.026; heterogeneity p = 0.001; I2 = 74.6%) and diastolic
blood pressure (MD: − 2.91 mmHg; 95% CI: − 4.15 to
− 1.67; comparison p < 0.001; heterogeneity p = 0.350;
I2 = 10.4%) (Appendix Fig. 3). Additionally, MRA sig-
nificantly increased serum levels of potassium (MD:
0.23 mmol/L; 95% CI: 0.19 to 0.28; comparison
p < 0.001; heterogeneity p = 0.539; I2 = 0.0%), but did
not affect blood levels of BNP/NT-proBNP (standard-
ized MD: − 0.00; 95% CI: − 0.29 to 0.28; comparison
p = 0.970; heterogeneity p = 0.015; I2 = 64.5%) com-
pared with placebo/control (Appendix Fig. 4).
Additional analyses
Sensitivity analysisThe effects ofMRA on echocardiographic,
functional, and systemic parameters of patients with HFpEF
seemed to be largely insensitive to different levels of correla-
tion coefficient (0.7, 0.9, and 0.8 or calculated based on given
study data) for imputation of standard deviations of within-
group changes (Table A7).
a b
Study ID
Edelmann (2013)
Mean diﬀerence in 
VO2 peak (95% CI)
%
weight
Upadhya (2017)
Kosmala (2016)
Kosmala (2017)
Overall (I-squared= 90.8%, p<0.001)
Test for overall eﬀect: Z=1.54 (p=0.124) 
Favors Control                               Favors MRA
NOTE: Weights are from random eﬀects analysis
-0.10 (-0.65,  0.45)
2.60 (1.36,  3.84)
-0.30 (-1.22,  0.62)
2.60 (1.36,  3.84)
1.22 (-0.33, 2.77)
27.17
23.82
25.59
23.43
100.00 Overall (I-squared= 0.0%, p=0.522)
Test for overall eﬀect: Z=2.40 (p=0.016) 
NOTE: Weights are from random eﬀects analysis
Favors Control                               Favors MRA
Upadhya (2017)
Kurrelmeyer (2014)
Edelmann (2013)
Deswal (2011) 2.00 (-26.82, 30.82)
-17.00 (-28.97, -5.03)
-6.00 (-36.57, 24.57)
-3.60 (-26.12, 18.92)
-11.56 (-21.00, -2.13)
10.72
62.20
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Fig. 4 Mean difference estimates of AVO2 peak and B 6-min walk distance (6-MWD) of MRA versus control
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Discussion
The main findings of this meta-analysis on the effect of MRA
in patients with HFpEF are: MRA (a) positively affect signif-
icant echocardiographic indices of cardiac structure and func-
tion, (b) slightly decrease 6-MWD, (c) increase levels of se-
rum potassium, and (d) decrease blood pressure.
Our study adheres to PRISMA reporting guidelines,
while our conclusions are based on evidence of moder-
ate to high quality (GRADE). Moreover, we exclusively
included randomized controlled trials of patients with
symptomatic HFpEF and not patients with asymptomatic
diastolic dysfunction, HFrEF or myocardial infarction,
as previous studies on the topic had done [11, 14, 20].
This was crucial in obtaining a comparable patient sam-
ple and analyzing multiple outcomes with low level of
heterogeneity. Additionally, as we screened studies up to
June 2018, we included in our quantitative analysis four
new, randomized studies, which contributed approxi-
mately 50% of the overall population and increased sta-
tistical power of analysis and significance of findings
[15–18]. Furthermore, our study meticulously studied a
range of echocardiographic, functional, and systemic pa-
rameters, thus providing the only, to date, comprehen-
sive review of these effects of MRA in the HFpEF
patient population.
Effect of MRA on echocardiographic parameters
Our study provides high-quality evidence to support that
MRA can exert significant, positive effects on diastolic
cardiac function (E/e′) and structure (LVEDD, LAVi) of
HFpEF patients. Beneficial effects of spironolactone on
clinical endpoints (HF hospitalizations) in these patients
have been previously reported [2]; however, failure of
one landmark trial to demonstrate superiority of
spironolactone regarding the prespecified primary outcome
has resulted in low MRA use among real-world HFpEF
patients [23]. Elevated E/e′ and left ventricular (LVEDD)
and left atrial dimensions (LAVi) have all been recognized
as predictors of adverse clinical outcome in this patient
population [24–30]. Whether these indices represent
markers of unchangeable, progressive disease or of poten-
tially reversible pathophysiological mechanisms remains
poorly elucidated; however, our current understanding of
the natural process of the disease and the close correlation
of these parameters with LV filling pressure suggests that
the latter is the most probable scenario underlining the
therapeutic potential of MRA [31]. Hence, the above echo-
cardiographic parameters could be considered as surrogate
markers of clinical outcomes and, until otherwise proven,
therapeutic targets. Furthermore, decrease of LVEDD and
LAVi also suggests that MRA induce reverse remodeling.
Effect of MRA on functional parameters
MRA use did not confer significant improvements in QoL
indices in the present meta-analysis, though the neutral results
may have been driven by the small number of studies
reporting QoL parameters, alongside the use of two different
questionnaires. Changes in NYHA class, though clinically
significant, were not reported as numerical variables in the
included studies and thus could not be quantitatively synthe-
sized. Finally, inconsistencies in the effect of MRA on func-
tional capacity of HFpEF patients were reported. Exercise
capacity, objectively assessed by peak VO2, was increased
by an increment of 1.2 ml/kg/min, though the result was sta-
tistically insignificant. Nonetheless, evaluation of this effect is
hindered by high heterogeneity. Conversely, MRA led to sig-
nificant, though mild decrease (11.5 m) in 6MWD in these
patients. This effect, which was largely driven by the results of
a single study [8], is contradictory to the other, physiological
and clinical, effects of MRA in patients with HFpEF. Thus,
further investigations are warranted to confirm the effect of
MRA on functional parameters.
Effect of MRA on systemic parameters
MRA use results in significant increases in serum potassium
levels. In particular, serum potassium increased in the inter-
vention group (from weighted mean 4.20 ± 0.0 to 4.39 ±
0.03 mmol/L) but decreased in the control group (from
weighted mean 4.21 ± 0.03 to 4.17 ± 0.06 mmol/L). These
findings are of clinical importance as previous studies have
demonstrated that lower levels of serum potassium are asso-
ciated with adverse outcome [32, 33], while high-normal
levels of potassium are accompanied by the most favorable
prognosis in HF patients [34]. On the other hand, MRA treat-
ment also leads to significant decreases in blood pressure.
Systolic (weighted mean 136.5 ± 8.4 to 130.7 ± 7.5 mmHg
for intervention vs. 136.2 ± 6.4 to 135.2 ± 5.5 mmHg for con-
trol) and diastolic blood pressure (weightedmean 77.5 ± 2.7 to
74.6 ± 3.0 mmHg for intervention vs. 77.9 ± 3.6 to 77.2 ±
4.4 mmHg for control) decreased in both groups; however,
magnitude of decrease was greater in the intervention group.
This effect, which has been previously reported [35], is en-
couraging as multiple studies support that treating hyperten-
sion is of high relevance in HFpEF [36, 37].
Clinical significance and future perspective
As mentioned above, the only multi-center study to date in-
vestigating the effect of MRA on outcomes failed to meet its
primary endpoint [2]. One must not, however, disregard the
signals of efficacy observed with the use of spironolactone
compared with placebo (reduction of HF hospitalizations by
17%), as well as the regional disparities that may have
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confounded the results [3, 4]. Particularly, patients enrolled on
the basis of the hospitalization criterion were much younger,
with fewer coexisting conditions and a lower risk profile com-
pared with patients enrolled on the basis of elevated natriuretic
peptides [3]. Moreover, the former also had a lower event rate,
a finding which contradicts a large body of HF literature. The
majority of patients from Russia and Georgia were enrolled in
the hospitalization stratum. Furthermore, based on the blood
analyses of 366 patients participating in the study who were
reporting to take the drug at 12 months, canrenone
(spironolactone’s metabolite) concentrations were undetect-
able in a significantly higher proportion of participants from
Russia than from the United States and Canada (30% vs. 3%),
strongly suggesting that the trial results obtained in Russia
may not reflect the true therapeutic response to spironolactone
[4]. Importantly, a post hoc analysis demonstrated that
spironolactone seemed to benefit patients in the Americas
but not those in Russia or Georgia [3].
Nonetheless, given that new trials aiming to evaluate the
effect of MRA on hard clinical endpoints are not expected for
several years [38], effect of MRA on other clinically relevant
parameters, such as the ones reported herein, may have im-
portant implications in informing physicians’ decision to ad-
minister MRA in HFpEF patients. Due to the relatively small
study populations and the limitations of the studies in the field,
several issues pertaining to the effects of MRA in HFpEF
remain unsettled. Namely, the question whether the lack of
significant effect of MRA on some studied parameters is due
to type II error needs to be clarified via future larger studies.
This pertains in particular to parameters which are either of
high clinical significance (QoL, NYHA, BNP, LVMi) or/and
for which a trend is reported in the present study (DT,
VO2peak). New studies will also be needed to confirm or
reject the unexpected result of decrease in 6-MWD with use
of MRA. This finding is paradoxical as exercise capacity has
been shown to increase (not decrease) alongside the aforemen-
tioned changes in cardiac function/structure [39].
Limitations
Our study shares the same weaknesses with previous system-
atic reviews in the field. First, heterogeneity in the criteria
employed to diagnose HFpEF and in the design of studies
represent major limitations, as they may have resulted in het-
erogeneous patient populations. Sample size was relatively
small; thus, type II error may explain some of the negative
findings of the analysis. Furthermore, study outcomes were
not consistently reported in all included trials. All these limi-
tations may in part be responsible for significant heterogeneity
observed among the pooled analyses for some outcomes.
Moreover, this meta-analysis was not performed on a patient
level but collected aggregate data from randomized studies
with different designs. This fact precluded performance of
subgroup analysis in specific subpopulation. Although most
included studies enrolled patients based on the same ejection
fraction threshold (≥ 50%), other distinct inclusion criteria
varied across studies. Hence, extrapolation of results to the
overall HFpEF population should be done with caution.
Despite these caveats, this meta-analysis may have signif-
icant therapeutic implications. In view of aggregate favorable
effects with no sound evidence of adverse effects, MRA treat-
ment should be considered as a treatment option for patients
with HFpEF.
Conclusions
In patients with HFpEF, MRA use leads to significant im-
provements in important indices of cardiac structure and func-
tion, potentially indicating a decrease in LV filling pressure
and reverse cardiac remodeling. MRA significantly increase
serum potassium, decrease blood pressure, but also decrease
6-MWD. Although this study represents the most comprehen-
sive, to date review of MRA effects on echocardiographic,
functional, and systemic parameters in HFpEF, larger prospec-
tive studies are warranted to provide definitive answers.
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